Vir Biotechnology director Ramasastry steps down; Robert More named audit chair
Saira Ramasastry left Vir Biotechnology's Board and Audit Committee effective May 26, 2026, citing a business conflict and stating her decision was not due to any disagreement with the Company. The Board named Robert More as Audit Committee chair and reduced its size from eight to seven members, and at the May 26, 2026 Annual Meeting stockholders elected three Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as auditor for 2026.
Key points
- Saira Ramasastry stepped down from the Board and the Audit Committee effective May 26, 2026, citing a business conflict.
- Robert More, MBA, was appointed Audit Committee chair, and the Board size was reduced from eight to seven members, both effective upon Ramasastry's departure.
- At the May 26, 2026 Annual Meeting, Robert More, Janet Napolitano, J.D., and Elliott Sigal, M.D., Ph.D., were elected Class I directors to serve until the 2029 annual meeting.
- Stockholders approved executive compensation on an advisory basis with 108,453,963 votes for and 11,863,405 against, and ratified Ernst & Young LLP for fiscal 2026 with 137,048,756 votes for.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 28, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.